Literature DB >> 18936326

Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition.

Matthew B West1, Gregg Rokosh, Detlef Obal, Murugesan Velayutham, Yu-Ting Xuan, Bradford G Hill, Rachel J Keith, Jürgen Schrader, Yiru Guo, Daniel J Conklin, Sumanth D Prabhu, Jay L Zweier, Roberto Bolli, Aruni Bhatnagar.   

Abstract

BACKGROUND: Inducible nitric oxide synthase (iNOS) is an obligatory mediator of the late phase of ischemic preconditioning, but the mechanisms of its cardioprotective actions are unknown. In addition, it remains unclear whether sustained elevation of iNOS in myocytes provides chronic protection against ischemia/reperfusion injury. METHODS AND
RESULTS: Constitutive overexpression of iNOS in transgenic mice (alpha-myosin heavy chain promoter) did not induce contractile dysfunction and did not affect mitochondrial respiration or biogenesis, but it profoundly decreased infarct size in mice subjected to 30 minutes of coronary occlusion and 24 hours of reperfusion. In comparison with wild-type hearts, isolated iNOS-transgenic hearts subjected to ischemia for 30 minutes followed by 40 minutes of reperfusion displayed better contractile recovery, smaller infarct size, and less mitochondrial entrapment of 2-deoxy-[(3)H]-glucose. Reperfusion-induced loss of NAD(+) and mitochondrial release of cytochrome c were attenuated in iNOS-transgenic hearts, indicating reduced mitochondrial permeability transition. The NO donor NOC-22 prevented permeability transition in isolated mitochondria, and mitochondrial permeability transition-induced NAD(+) loss was decreased in wild-type but not iNOS-null mice treated with the NO donor diethylene triamine/NO 24 hours before ischemia and reperfusion ex vivo. iNOS-mediated cardioprotection was not abolished by atractyloside. Reperfusion-induced production of oxygen-derived free radicals (measured by electron paramagnetic resonance spectroscopy) was attenuated in iNOS-transgenic hearts and was increased in wild-type hearts treated with the mitochondrial permeability transition inhibitor cyclosporin A.
CONCLUSIONS: Cardiomyocyte-restricted expression of iNOS provides sustained cardioprotection. This cardioprotection is associated with a decrease in reperfusion-induced oxygen radicals and inhibition of mitochondrial swelling and permeability transition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18936326      PMCID: PMC2763350          DOI: 10.1161/CIRCULATIONAHA.108.791533

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

Review 1.  The late phase of preconditioning.

Authors:  R Bolli
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  Activation of mitochondrial ATP-dependent potassium channels by nitric oxide.

Authors:  N Sasaki; T Sato; A Ohler; B O'Rourke; E Marbán
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

Review 3.  Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection.

Authors:  Elizabeth Murphy
Journal:  Circ Res       Date:  2004-01-09       Impact factor: 17.367

4.  Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart.

Authors:  Sabzali A Javadov; Samantha Clarke; Manika Das; Elinor J Griffiths; Kelvin H H Lim; Andrew P Halestrap
Journal:  J Physiol       Date:  2003-04-11       Impact factor: 5.182

5.  Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?

Authors:  Derek J Hausenloy; Helen L Maddock; Gary F Baxter; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

6.  Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide.

Authors:  Enzo Nisoli; Emilio Clementi; Clara Paolucci; Valeria Cozzi; Cristina Tonello; Clara Sciorati; Renata Bracale; Alessandra Valerio; Maura Francolini; Salvador Moncada; Michele O Carruba
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

Review 7.  Role of the mitochondrial permeability transition in myocardial disease.

Authors:  James N Weiss; Paavo Korge; Henry M Honda; Peipei Ping
Journal:  Circ Res       Date:  2003-08-22       Impact factor: 17.367

8.  Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor.

Authors:  Richard G Black; Yiru Guo; Zhi-Dong Ge; Sidney S Murphree; Sumanth D Prabhu; W Keith Jones; Roberto Bolli; John A Auchampach
Journal:  Circ Res       Date:  2002-07-26       Impact factor: 17.367

9.  Preconditioning delays Ca2+-induced mitochondrial permeability transition.

Authors:  Laurent Argaud; Odile Gateau-Roesch; Lara Chalabreysse; Ludovic Gomez; Joseph Loufouat; Françoise Thivolet-Béjui; Dominique Robert; Michel Ovize
Journal:  Cardiovasc Res       Date:  2004-01-01       Impact factor: 10.787

Review 10.  Preconditioning the myocardium: from cellular physiology to clinical cardiology.

Authors:  Derek M Yellon; James M Downey
Journal:  Physiol Rev       Date:  2003-10       Impact factor: 37.312

View more
  53 in total

1.  Postischemic deactivation of cardiac aldose reductase: role of glutathione S-transferase P and glutaredoxin in regeneration of reduced thiols from sulfenic acids.

Authors:  Karin Wetzelberger; Shahid P Baba; Mahesh Thirunavukkarasu; Ye-Shih Ho; Nilanjana Maulik; Oleg A Barski; Daniel J Conklin; Aruni Bhatnagar
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  Toll-like receptor 7/8 agonist resiquimod induces late preconditioning in neonatal cardiac myocytes.

Authors:  Yong-yi Wang; Sha Liu; Feng Lian; Wen-gang Yang; Song Xue
Journal:  Acta Pharmacol Sin       Date:  2011-04-25       Impact factor: 6.150

3.  Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor.

Authors:  Peter Kanellakis; Giovanna Pomilio; Alex Agrotis; Xiaoming Gao; Xiao-Jun Du; David Curtis; Alexander Bobik
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Netrin-1 abrogates ischemia/reperfusion-induced cardiac mitochondrial dysfunction via nitric oxide-dependent attenuation of NOX4 activation and recoupling of NOS.

Authors:  Kin Lung Siu; Christopher Lotz; Peipei Ping; Hua Cai
Journal:  J Mol Cell Cardiol       Date:  2014-07-24       Impact factor: 5.000

Review 5.  Rodent models of heart failure: an updated review.

Authors:  A C Gomes; I Falcão-Pires; A L Pires; C Brás-Silva; A F Leite-Moreira
Journal:  Heart Fail Rev       Date:  2013-03       Impact factor: 4.214

6.  Cardioprotective effect of thyroid hormone is mediated by AT2 receptor and involves nitric oxide production via Akt activation in mice.

Authors:  Ivson Bezerra da Silva; Dayane Aparecida Gomes; Natalia Alenina; Michael Bader; Robson Augusto Dos Santos; Maria Luiza M Barreto-Chaves
Journal:  Heart Vessels       Date:  2017-12-07       Impact factor: 2.037

7.  Piecewise nonlinear mixed-effects models for modeling cardiac function and assessing treatment effects.

Authors:  Hyejeong Jang; Daniel J Conklin; Maiying Kong
Journal:  Comput Methods Programs Biomed       Date:  2012-12-17       Impact factor: 5.428

8.  Involvement of nitric oxide in a rat model of carrageenin-induced pleurisy.

Authors:  Masahiro Iwata; Shigeyuki Suzuki; Yuji Asai; Takayuki Inoue; Kenji Takagi
Journal:  Mediators Inflamm       Date:  2010-06-02       Impact factor: 4.711

Review 9.  Bench-to-bedside review: nitric oxide in critical illness--update 2008.

Authors:  Steven M Hollenberg; Ismail Cinel
Journal:  Crit Care       Date:  2009-07-16       Impact factor: 9.097

10.  Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms.

Authors:  Ian Moench; Howard Prentice; Zach Rickaway; Herbert Weissbach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.